A practical approach to promoting adherence to immunosuppressive medication after renal transplantation

Current Opinion in Nephrology and Hypertension

Volumn 15, Issue SUPPL. 2, 2006, Pages

  Schäfer Keller, Petra ^a   Lyon, Sue ^b   Van Gelder, Frank ^c   De Geest, Sabina ^a,d  

^a UNIVERSITY OF BASEL   (Switzerland)

^b University Hospital Gasthuisberg ^*

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Chronic disease model; Immunosuppression; Non adherence; Renal transplantation

Indexed keywords

ANTI ACNE AGENT; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TACROLIMUS;

ACNE; ACUTE GRAFT REJECTION; CORRELATION ANALYSIS; DENTAL CARE; DOCTOR PATIENT RELATION; GINGIVA HYPERPLASIA; GRAFT FAILURE; HEALTH CARE SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MORTALITY; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SOCIOECONOMICS; UNSPECIFIED SIDE EFFECT;

EID: 33748068833     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000238111.31598.a2     Document Type: Review

References (42)

1. Nankivell BJ, Borrows RJ, Fung CL-S, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78:557-565.
2. Gordon EJ, Prohaska T, Siminoff LA, et al. Can focusing on self-care reduce disparities in kidney transplantation outcomes? Am J Kidney Dis 2005; 45:935-940.
3. Nevins TE, Matas AJ. Medication noncompliance: another iceberg's tip. Transplantation 2004; 77:776-778.
4. World Health Organisation. Adherence to long-term therapies: evidence for action. Geneva: World Health Organisation; 2003.
5. Nevins TE, Kruse L, Skeans MA, Thomas W. The natural history of azathioprine compliance after renal transplantation. Kidney Int 2001; 60:1565-1570.
6. De Geest S, Abraham I, Moons P, et al. Late acute rejection and subclinical noncompliance with cyclosporine therapy in heart transplant recipients. J Heart Lung Transplant 1998; 17:854-863.
7. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
8. Denhaerynck K, Dobbels F, Cleemput I, et al. Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review. Transplant Int 2005; 18:1121-1133.
9. Dobbels F, Van Damme-Lombaert R, Vanhaecke J, De Geest S. Growing pains: non-adherence with the immunosuppressive regimen in adolescent transplant recipients. Pediatr Transplant 2005; 9:381-390.
10. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996; 348:383-386.
11. Desmyttere A, Dobbels F, Cleemput I, De Geest S. Noncompliance with immunosuppressive medication in organ transplantation: is it worth worrying about? Acta Gastro-Enterologica Belgica 2005; LXVIII:347-352.
12. Russell L. Medication noncompliance: perceptions of transplant healthcare providers. Dial Transplant 2005; 34:301-307.
13. Cleemput I, Kesteloot K, Vanreterghem Y, De Geest S. The economic implications of non-adherence after renal transplantation. Pharmacoeconomics 2004; 22:1217-1234.
14. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001; 323:1300-1303.
15. De Geest S, Borgermans L, Gemoets H, et al. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation 1995; 59:340-347.
16. Sketris I, Waite N, Grobler K, et al. Factors affecting compliance with cyclosporine in adult renal transplant patients. Transplant Proc 1994; 26:2538-2541.
17. Raiz LR, Kilty KM, Henry ML, Ferguson RM. Medication compliance following renal transplantation. Transplantation 1999; 68:51-55.
18. Douglas S, Blixen C, Bartucci MR. Relationship between pretransplant noncompliance and posttransplant outcomes in renal transplant recipients. J Transplant Coord 1996; 6:53-58.
19. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002; 40:794-811.
20. Siegal BR, Greenstein SM. Postrenal transplant compliance from the perspective of African-Americans, Hispanic-Americans, and Anglo-Americans. Adv Ren Replace Ther 1997; 4:46-54.
21. Fierz K, Steiger J, Denhaerynck K, et al. Prevalence, severity and correlates of alcohol use in adult renal transplant recipients. Clin Transplant 2006; 20:171-178.
22. Hanrahan JS, Eberly C, Mohanty PK. Substance abuse in heart transplant recipients: a 10-year follow-up study. Prog Transplant 2001; 11:285-290.
23. Chisholm MA, Lance CE, Mulloy LL. Patient factors associated with adherence to immunosuppressive therapy in renal transplant recipients. Am J Health System Pharm 2005; 62:1775-1781.
24. Chisholm MA, Mulloy LL, DiPiro JT. Comparing renal transplant patients' adherence to free cyclosporine and free tacrolimus immunosuppressant therapy. Clin Transplant 2005; 19:77-82.
25. Moons P, Vanrenterghem Y, van Hooff JP, et al. Steroids may compromise quality of life of renal transplant recipients on a tacrolimus-based regimen. Transplant Proc 2002; 34:1691-1692.
26. Peters TG, Spinola KN, West JC, et al. Differences in patient and transplant professional perceptions on immunosuppression-induced cosmetic side-effects. Transplantation 2004; 78:537-543.
27. Butkus DE, Meydrech EF, Raju SS. Racial differences in the survival of cadaveric renal allografts. Overrriding effects of HLA matching and socioeconomic factors. N Engl J Med 1992; 327:840-845.
28. Weng FL, Israni AK, Joffe MM, et al. Race and electronically measured adherence to immunosuppressive medication after deceased donor renal transplantation. J Am Soc Nephrol 2005; 16:1839-1848.
29. Denhaerynck K, Desmyttere A, Dobbels F, et al. Nonadherence with immunosuppressive drugs: US compared with European kidney transplant recipients. Prog Transplant 2006; 16:133-141.
30. EBPG Expert Group on Renal Transplantation. European Best Practice Guidelines for Renal Transplantation. Section IV: long-term management of the transplant recipient. Nephrol Dial Transplant 2002; 17 (Suppl. 4):1-67.
31. World Health Organisation. Innovative care for chronic conditions: building blocks for action. Geneva: World Health Organisation; 2002.
32. Haynes RB, Yao X, Degani A, et al. Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005; 4:CD000011.
33. De Geest S, Schäfer-Keller P, Denherynck K, et al. Supporting medication adherence in renal transplantation (smart): a pilot study RCT to improve adherence with immunosuppressive regimen. Clin Transplant 2006; 20:359-368.
34. Chang CF, Winsett RP, Gaber AO, Hathaway DK. Cost-effectiveness of posttransplantation quality of life intervention among kidney recipients. Clin Transplant 2004; 18:407-414.
35. Dew MA, Goycoolea JM, Harris RC, et al. An internet-based intevention designed to improved psychosocial outcomes in heart transplant recipients and family caregivers: development and evaluation. J Heart Lung Transplant 2004; 23:745-758.
36. Traiger GL, Bui LL. A self-medication administration program for transplant recipients. Crit Care Nurse 1997; 17:71-79.
37. Butler JA, Peveler RC, Roderick P, et al. Modifiable risk factors for nonadherence to immunosuppressants in renal transplant recipients: a cross-sectional study. Nephrol Dial Transplant 2004; 19:3144-3149.
38. Loghman-Adham M. Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care 2003; 9:155-171.
39. Marinker M, Shaw J. Not to be taken as directed. BMJ 2003; 326:348-349.
40. Artz MA, Boots JM, Ligtenberg G, et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004; 4:937-945.
41. Ponticelli C. Steroid-sparing strategies. Transplant Proc 2005; 37:3597-3599.
42. Loucaidou M, Borrows R, Cairns T, et al. Late steroid withdrawal for renal transplant recipients on tacrolimus and MMF is safe. Transplant Proc 2005; 37:1795-1796.